linagliptin+metformin (Jentadueto)

following an abbreviated submission:

linagliptin plus metformin tablets (Jentadueto®) is accepted for restricted use within NHS Scotland.

Indication under review: Treatment of adult patients with type 2 diabetes mellitus:

• as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.
• in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.

SMC restriction: to use in patients for whom a combination of linagliptin and metformin is an appropriate choice of therapy and these fixed-doses are considered appropriate.